Cosmax BTI, Inc (044820) Fair Value & Analysis
Consumer Defensive · KR · Market cap 170B KRW
Fair value as of: Jul 6, 2026
From 23 valuation models · updated today
Share price +7.5% over the past month.
Price vs Fair Value (12 months)
12‑month range 11,450 KRW – 23,510 KRW · fair‑value band 31,784 KRW – 64,960 KRW · the 19,490 KRW price screens below the 51,968 KRW fair value. As of Jul 6, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Cosmax BTI, Inc (044820) currently trades at 19,490 KRW, while our model-based Fair Value estimate is 51,968 KRW — implying the stock looks roughly 166.6% undervalued today. We read business quality at 52/100 (solid quality), in the Consumer Defensive sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, Cosmax BTI, Inc generated revenue of 696B KRW at a net margin of 6.1%. Revenue grew 33.0% year over year. It earns a return on equity of 13.4%. Net debt stands at 410B KRW. Fundamentals as of Jul 6, 2026
Our scenario range runs from 31,784 KRW (bear case) to 64,960 KRW (bull case); at 19,490 KRW, the current price sits below that range. The share trades about 18% below its 52-week high and 73% above its 52-week low, currently above its 200-day average. For context, the median of 10 Consumer Defensive peers we cover trades at -27% fair-value upside — at 167%, 044820 screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 6, 2026. TTM = trailing twelve months.
About the company
Cosmax BTI, Inc. engages in the research, development, production, and sale of cosmetics, health functional foods, pharmaceuticals, and special containers in South Korea. The company offers cosmetics products, including skincare, mask, cleansing, hair, bath and body, sun care, makeup, cushion, eye and lip makeup, nail, and fragrance products; baby and child cosmetic products; Korean herbal cosmetics; and cosmeceuticals. It also provides health supplement products in form of gels, capsules, and powders; and medical devices. In addition, the company exports its products. Cosmax BTI, Inc. was founded in 1984 and is headquartered in Seongnam-si, South Korea.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Cosmax BTI, Inc reported revenue of 645B KRW in FY2025 versus 576B KRW in FY2021, a compound +2.9%/yr. Reported net income was 29.2B KRW in FY2025, compounding +19.9%/yr from FY2021.
Is 044820 fairly valued? → Check now
Similar stocks
10 more Packaged Foods stocks, each showing price versus our Fair Value estimate (as of Jul 6, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Nestlé S.A NESN | CHF 79.44 | CHF 50.99 | -36% |
| Foshan Haitian Flavouring and Food Company 603288 | ¥34.03 | ¥23.66 | -30% |
| Nestlé India Limited NESTLEIND | ₹1,386 | ₹278.10 | -80% |
| Grupo Bimbo, S.A. BIMBOA | 57.10 MXN | 83.34 MXN | +46% |
| Uni-President Enterprises Corp 1216 | 75.60 TWD | 55.53 TWD | -27% |
| Britannia Industries Limited BRITANNIA | ₹5,171 | ₹1,966 | -62% |
| Tata Consumer Products Limited TATACONSUM | ₹1,131 | ₹339.05 | -70% |
| ICBP ICBP | 6,600 IDR | 14,500 IDR | +120% |
| Samyang Foods Co 003230 | 1,000,000 KRW | 1,010,543 KRW | +1% |
| PT Indofood Sukses Makmur Tbk INDF | 6,750 IDR | 25,554 IDR | +279% |
Explore undervalued stocks
More undervalued Consumer Defensive stocks →
Frequently asked questions
Is Cosmax BTI, Inc (044820) undervalued?
What is the fair value of 044820?
What is the quality score of 044820?
What is the revenue of Cosmax BTI, Inc (044820)?
What is the net profit margin of 044820?
Does Cosmax BTI, Inc pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.